Form 4: Metagenomi Director Willard H. Dere Acquires 21,000 Stock Options

Metagenomi, Inc. Director Willard H. Dere has acquired 21,000 stock options with an exercise price of $1.57, set to vest based on service conditions.

Summary

• Willard H. Dere, a Director of Metagenomi, Inc. (MGX), acquired 21,000 stock options.
• The options have an exercise price of $1.57 per share.
• The transaction date for the acquisition was June 10, 2025.
• These options are for Common Stock, with each option representing the right to buy one share.
• The options will expire on June 9, 2035.
• Vesting occurs on the earlier of the one-year anniversary of the grant date (June 10, 2026) or the date of the Company's 2026 annual meeting of stockholders, contingent on continued service.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive signal, indicating confidence and aligning interests. It's a routine compensation event, so not extremely high impact, but positive nonetheless.

Positives

• The acquisition of stock options by a director indicates alignment of interests between management and shareholders, as the director's compensation is tied to the company's future stock performance.
• The grant of options at an exercise price of $1.57 provides an incentive for the director to contribute to the company's growth and increase in share value.

Negatives

• No negative information was reported in this Form 4 filing, as it details an acquisition of options rather than a sale.

Risks

• No specific risks were mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance, beyond the vesting schedule of the granted options.

Industry Context

This filing is a routine disclosure of an insider transaction, common across all industries for publicly traded companies. It reflects standard equity compensation practices for directors in the biotechnology or genomics sector, where Metagenomi operates.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice for public companies across various industries, including biotechnology. The specific terms, such as the number of options (21,000) and the exercise price ($1.57), are typical for director compensation packages, aligning their interests with long-term shareholder value. Without specific comparable companies' director compensation details, a direct quantitative comparison is not feasible from this document alone, but the mechanism is standard.

Related Party Transactions

• The grant of 21,000 stock options to Willard H. Dere, a Director of Metagenomi, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, as the director benefits from an increase in the company's stock price. This could be seen as a positive for long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options are subject to a vesting schedule, which will occur on the earlier of the one-year anniversary of the grant date (June 10, 2026) or the date of the Company's 2026 annual meeting of stockholders.
• The Reporting Person must maintain continued service with the Issuer for the options to vest.
• The options will remain exercisable until their expiration date of June 9, 2035, assuming they vest.

Key Dates

Keywords

Metagenomi, MGX, Form 4, SEC filing, stock options, insider transaction, director compensation, equity grant, beneficial ownership